Based on the Unity Biotechnology Inc stock forecast from 2 analysts, the average analyst target price for Unity Biotechnology Inc is USD 4.86 over the next 12 months. Unity Biotechnology Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Unity Biotechnology Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Unity Biotechnology Inc’s stock price was USD 0.86. Unity Biotechnology Inc’s stock price has changed by +24.40% over the past week, -5.12% over the past month and -45.48% over the last year.
No recent analyst target price found for Unity Biotechnology Inc
No recent average analyst rating found for Unity Biotechnology Inc
Company Overview Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. Read Less
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye,...Read More
Frequently Asked Questions About Unity Biotechnology Inc (UBX) Stock
Based on ratings from 2 analysts Unity Biotechnology Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on UBX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for UBX is USD 4.86 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 2.
UBX stock's Price/Earning ratio is 4.60.
Our analysis grades UBX stock's Price / Earning ratio at F. This means that UBX stock's Price/Earning ratio is above 47% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this UBX may be fairly valued for its sector
The last closing price of UBX's stock was USD 0.86.
The most recent market capitalization for UBX is USD 0.01B.
Based on targets from 2 analysts, the average taret price for UBX is projected at USD 4.86 over the next 12 months.
This means that UBX's stock price may go up by +467.49% over the next 12 months.
We can't find any ETFs which contains Unity Biotechnology Inc's stock.
As per our most recent records Unity Biotechnology Inc has 16 Employees.
Unity Biotechnology Inc's registered address is 285 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from Unity Biotechnology Inc's website at https://unitybiotechnology.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Unity Biotechnology Inc (UBX) Stock
Based on ratings from 2 analysts Unity Biotechnology Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on UBX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for UBX is USD 4.86 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 2.
UBX stock's Price/Earning ratio is 4.60.
Our analysis grades UBX stock's Price / Earning ratio at F. This means that UBX stock's Price/Earning ratio is above 47% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this UBX may be fairly valued for its sector
The last closing price of UBX's stock was USD 0.86.
The most recent market capitalization for UBX is USD 0.01B.
Based on targets from 2 analysts, the average taret price for UBX is projected at USD 4.86 over the next 12 months.
This means that UBX's stock price may go up by +467.49% over the next 12 months.
We can't find any ETFs which contains Unity Biotechnology Inc's stock.
As per our most recent records Unity Biotechnology Inc has 16 Employees.
Unity Biotechnology Inc's registered address is 285 East Grand Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from Unity Biotechnology Inc's website at https://unitybiotechnology.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for UBX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
